RE-EQUIP (Sales Effectiveness Program - Victoza)
Liraglutide provides all the benefits except:
A) Reduction in blood glucose levels
B) Reduction in diastolic blood pressure
C) Clinically significant weight loss
D) Improvement in beta cell function
Which of the following is false regarding liraglutide administration?
A) Once – daily dosing
B) Can be given in the morning only
C) Dosing independent of meals
D) No need for additional self –monitoring plasma glucose
Liraglutide monotherapy versus sulfonylureas was evaluated in :
A) LEAD -1
B) LEAD -2
C) LEAD -3
D) LEAD -4
Liraglutide + metformin and/or SU versus Exenatide + metformin and/or SU was evaluated in :
a) LEAD- 3
B) LEAD- 4
c) LEAD- 5
D) LEAD- 6
In LEAD -3 study the percentage of patients with HbA1c reduction less than 7% with 1.2 mg liraglutide , 1.8 mg liraglutide and Glimepiride are:
A) 27.8, 50.9 and 42.8
B) 42.8, 50.9 and 27.8
C) 50.9, 27.8 and 42.8
d) 27.8, 42.8 and 50.9
In LEAD -5 study percentage reduction in HbA1c with liraglutide and glargine is :
A) 1.33 % and 1.09%
B) 1.09% and 1.33%
C) 2.5 % and 3.1 %
d) 3.1% and 2.5%
Liraglutide vs. DPP-4i core and extension 1, the reduction on HbA1c with siatgliptin , liraglutide: (1) 1.2 mg and liraglutide 1.8 mg over 52 weeks is :
A) 1.51% , 1.29% and .88 %
B) 1.29% , 1.51% and .88 %
c) .88 % , 1.29% and 1.51%
D) .88% , 1.51% and
Liraglutide vs. DPP-4i core and extension 1 , the percentage of patients reaching targets of HbA1c of < 7% with sitagliptin , 1.2 mg liraglutide and 1.8 mg liraglutide is :
A) 50.3 , 27.1 and 63.3
B) 27.1 , 50.3 and 63.3
C) 63.6 , 50.3 and 27.1
D) 27.1 , 63.3 and 50.3
Liraglutide vs. DPP-4i core and extension 1 , the percentage of patients reaching targets of HbA1c of < 6.5% with sitagliptin , 1.2 mg liraglutide and 1.8 mg liraglutide is :
A) 40.4 , 16.8 and 24.3
B) 16.8, 40.4 and 24.3
c) 16.8 , 24.3 and 40.4
d) 24.3, 404.4 and 16.8
According to ADA , Zinman et al. Diabetologia 2009;52(Suppl. 1):S291–2 composite end point 1 inculdes all of the following except :
A) HbA1c <7.0%
B) no weight gain
C) no confirmed hypoglycaemia (minor or severe)
D) SBP <130 mmHg
According to ADA,Zinman et al. Diabetes 2009;58(Suppl. 1):A143–4 composite end point includes all of the folowing except :
A) HbA1c <7.0%
B) no weight gain
c) no confirmed hypoglycaemia (minor or severe)
D) SBP <130 mmHg
According to the Zinman B et al. Diabetes Obes Metab 2012;14:77–82 the percentage of patients reaching composite end point 1 with liraglutide 1.8mg , liraglutide 1.2mg , exenatide and sitagliptin is :
A) 11, 25, 32 and 40
B) 25, 40 , 11 and 32
C) 40 , 32 , 25 and 11
d) 32 , 25 , 40 and 11
According to the Zinman et al. Diabetes 2009;58(Suppl. 1):A143–4 the percentage patients reaching composite end point 2 with liraglutide 1.8mg , liraglutide 1.2mg and exenatide is :
a) 14 , 21 and 25
b) 25, 21 and 14
C) 21 , 25 and 14
D) 35 , 21 and 14
According to the SMPC of liraglutide, exenatide and lixisenatide , the percentage of patients with positive antibody status is :
A) 69.8, 38 and 8.6
B) 38, 69.8 and 8.
C) 8.6 , 38 and 69.8
D) 10.4 40.3 and 69.8
According to Kapitza et al , the reduction with liraglutide and lixisenatide in HbA1c(%) in 28 days is :
A) .30 and .60
B) .51 and .21
C) .22 and .51
D) .60 and .30
According to Kapitza et al , the reduction with liraglutide and lixisenatide in weight (%) in 28 days is :
a) 3.4 and 1.6
b) 1.6 and 2.4
c) 2.4 and 1.6
d) 1.6 and 3.4
In Harmony -7 liraglutide 1.8 mg is compared with :
A) Exenatide
B) Albiglutide
C) Lixisenatide
D) Bydureon
In DURATION -6 liraglutide is compared with :
A) Exenatide
B) Albiglutide
C) Lixisenatide
d) Bydureon
In Harmony – 7 the reduction in HbA1c (%) with liraglutide and albiglutide is :
a) .8 and 1.0
b) 1.0 and .8
C) 1.2 and .8
d) .8 and 1.3
LEADER trial was initiated in …………….
A) 2009
b) 2010
C) 2011
d) 2012
LEADER trial included ……………. Patients who were at high risk for cardiovascular disease
A) Type 1 diabetes
B) Type 2 diabetes
C) Both
D) None of the above
In LEADER trial ……………. Number of patients underwent randomization
A) 9320
B) 9430
C) 9340
D) 9230
In LEADER trial patients were randomized to
A) Liraglutide : Glargine
B) Liraglutide : Placebo
C) Liraglutide : Exenatide
D) Liraglutide : Semaglutide
Primary Endpoint of LEADER trial was the occurrence of:
A) death from any cause or Death from MI or death from stroke
B) death from MI or non-fatal MI or non-fatal stroke
C) death from cardiovascular causes or non-fatal MI or non-fatal stroke
D) Any death from any cause
Maximum dose of liraglutide in LEADER study was:
A) 1.2 mg
B) 1.8 mg
c) 3.0 mg
D) 6.0 mg
{"name":"RE-EQUIP (Sales Effectiveness Program - Victoza)", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"Enter your initials without space","img":"https://cdn.poll-maker.com/156554/9.jpg?sz=1200-000000100053"}
More Quizzes
Oh no. Be an idol. (BE HONEST ON WHAT YOU WOULD DO)
13612
Chat 2 Exam 3
15829
Which Dollevoet Are You?
1050
Quiz
100
Kultúr Fröccs - Jóbarátok-kvíz - Kinek a szájából hangzott el?
1050
�Exam Test Review
1050
Bobby the Bee's Quiz Level 3
20100
The Epic Nature Quiz
840
Chromebook Quiz 411
13622
Zachary quiz
1585
Snack Slogans
840
Test
210